Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Peptilogics Strengthens Leadership Team with Executive Appointments

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, announced two executive appointments to strengthen and expand its leadership team. Atul Deshpande, Ph.D., MBA, A-PMP, has been appointed to Chief Strategy Officer and Nicholas Pachuda, DPM, has been promoted to Chief Operating Officer.

“We continue to break new ground in peptide drug development, both with PLG0206, our first-in-class engineered peptide in clinical trials for the treatment of periprosthetic joint infection, and with Nautilus, our deep learning-based computational platform for peptide drug discovery and design. The addition of Dr. Deshpande to our executive team and the promotion of Dr. Pachuda reflects the growth of our organization and the necessary leadership to advance our pipeline and technology initiatives,” said Jonathan Steckbeck, Ph.D., Founder and CEO of Peptilogics. “Nick’s deep understanding of the unique opportunity for orthopedic therapeutics and Atul’s comprehensive experience in identifying and building new markets will be invaluable as we advance our programs through the clinic and toward market.”

Recommended AI News: ITsavvy Announces Acquisition of Technology Resource Advisors K-12 Computing

Atul Deshpande, Ph.D., MBA, A-PMP, Chief Strategy Officer, Peptilogics

Dr. Deshpande will be responsible for the overall company strategy and business development at Peptilogics. He previously served as the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS). Before joining IMMEDIATE Therapeutics, he was the Chief Strategy Officer and Head of US Operations for Harbour BioMed (HBM). Dr. Deshpande also served as the Global Operations Head for the Dupixent Franchise with Sanofi, where he led marketing, market access and supply chain operations to launch Dupixent in several markets across the world for Atopic Dermatitis and in major markets for Asthma. Previously, he led the operations for Sanofi’s Immunology R&D portfolio and was also responsible for new product planning and in-licensing evaluations.

“I am impressed by the work Peptilogics has already accomplished to accelerate peptide discovery at an unprecedented pace, combining biopharma expertise, deep learning and purpose-built super-computing,” said Dr. Deshpande. “Peptides offer a unique value proposition by allowing us to overcome many of the limitations of small and large molecules. I am excited to work with this team to engineer peptide therapeutics that address unmet medical and access needs across the world.”

Related Posts
1 of 30,135

Recommended AI News: New Arizent Research, the Future of the Data-Driven Workplace, Analyzes Artificial Intelligence Implementation in Financial Services and the Benefits It Provides

Nicholas Pachuda, DPM, Chief Operating Officer, Peptilogics

In his new role, Dr. Pachuda will be responsible for refining and implementing the company’s strategy, operations, and long-range planning. In addition, he will continue to lead Peptilogics’ development functions, now to include regulatory and quality, while supporting business development and M&A.

Dr. Pachuda previously served as Senior Vice President of Portfolio and Development at Peptilogics. Dr. Pachuda joined Peptilogics in 2020, following 30 years of clinical and business experience, most recently at Johnson & Johnson, where he led External Innovation for the world’s largest orthopedic device franchise.

“At its core, life science innovation is only possible because of those who have dedicated their lives to improving treatment options for patients with challenging health issues,” said Dr. Pachuda. “I am passionate about developing teams that are willing to overcome challenges, forge new paths and take the risks required to impact real change, and I am grateful to be surrounded by a like-minded team at Peptilogics. I look forward to building upon the foundation of success we have created toget

Recommended AI News: Cybersecurity for AI Solutions Provider TrojAI Inc. Closes $3 Million Seed Round

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.